Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04144348 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
A Phase 1 study of Human Metapneumovirus and Human Parainfluenza Infection, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 19
- Study locations
NCT04144348 is a Phase 1 study of Human Metapneumovirus and Human Parainfluenza Infection that has completed, run by ModernaTX. The registered enrollment target is 51 participants. The trial reports 19 study locations across 12 states.
The verdict
NCT04144348, a Phase 1 study of Human Metapneumovirus and Human Parainfluenza Infection, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 19
- Study locations
Study Summary
This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose levels in children (12 to 59 months of age) with serologic evidence of prior exposure. The safety profile of the adult cohort will permit enrollment of the pediatric cohort.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1653
Study Locations (19)
Nebraska
- Meridian Clinical Research, LLC - Lincoln
- Meridian Clinical Research - Norfolk
- Meridian Clinical Research, LLC - Omaha
New York
- UHS Primary Care - Binghamton
- Child Healthcare Associates - Liverpool
- Child Healthcare Assoc. - Syracuse
Texas
- Crossroads Clinical Research - Corpus Christi
- University of Texas Medical Branch (UTMB) - Galveston
- Tekton Research Inc - San Antonio
Kansas
- Heartland Research Associates LLC - El Dorado
- Heartland Research Associates LLC - Newton
Alabama
- Central Research Associates Inc - Birmingham
District of Columbia
- Meridian Clinical Research - Washington D.C.
Idaho
- Clinical Research Prime - Idaho Falls
Louisiana
- MedPharmics - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04144348
The ClinicalTrials.gov registry entry for NCT04144348 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Metapneumovirus and Human Parainfluenza Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04144348 reports 19 study locations spanning 12 distinct geographic areas - top geographies include Nebraska, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT04144348 about?
NCT04144348 is a clinical study titled "Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure". This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose levels in children (12 to 59 months of age) with serologic evidence of prio...
What is the current status of trial NCT04144348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2019-11-04. Estimated completion is 2022-12-20.
What conditions does trial NCT04144348 study?
This clinical trial studies the following conditions: Human Metapneumovirus and Human Parainfluenza Infection.
What interventions are being tested in trial NCT04144348?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1653 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04144348?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04144348 being conducted?
This trial has 19 study locations across Alabama, District of Columbia, Idaho, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.